Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Microneedle technology integrated with diverse therapeutic modalities for hair regrowth in alopecia

Gong M., Jiang Z., Yang Z., Chen T., Hu W., Zhou C.

Clinical Trial on Hair Loss, Hair Regeneration, published in Acta Pharm Sin B (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Acta Pharm Sin B (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42368577
PMCID
PMC13304719
DOI
10.1016/j.apsb.2026.03.006

Abstract (original English)

Alopecia profoundly impacts an individual's appearance, quality of life, and social well-being, with its prevalence increasing with age. Conventional treatments, such as topical minoxidil and oral finasteride, suffer from limitations like inefficient drug delivery, side effects, and inconsistent efficacy. Other therapies, like hair transplantation, biologics and low-level laser therapy (LLLT), also face some constraints in practical application. Microneedles (MNs), as an emerging transdermal drug delivery system (TDDS), enable efficient local delivery of therapeutic agents to hair follicles in the balding scalp by physically penetrate stratum corneum. Through enhanced drug permeability and activation of follicular regeneration pathways, MN-combined strategies have ignited considerable research interest. This review outlines the advances in MN-mediated alopecia treatments over the past five years and underscores their potential to enhance hair regrowth efficacy, including MN-assisted delivery of chemical drugs, natural compounds, biologics, nanomedicines, stem cells, and LLLT. Additionally, this review also summarizes the advances in clinical trials of MN-combined therapies for alopecia over the past five years, highlighting the noticeable disconnection in research focus between basic research and clinical trials. In summary, this review aims to provide critical insights and fut

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research